Sunny Kumar | Nanobiotechnology | Young Scientist Award

Mr. Sunny Kumar | Nanobiotechnology | Young Scientist Award

Researcher, CSIR-Indian Institute Of Chemical Biology, India

Mr. Sunny Kumar is an emerging researcher in cancer biology and nanomedicine, recognized for his interdisciplinary contributions that bridge molecular oncology, tumor microenvironment studies, and nanotechnology-driven therapeutics. With an h-index of 6, 11 publications, and 148 citations (as indexed in Scopus), his research reflects both productivity and impact within translational cancer science. His primary research focuses on elucidating the molecular mechanisms underlying glioma, colorectal, and breast cancer progression, emphasizing protein quality control systems such as the ubiquitin-proteasome system and their regulatory influence on oncogenic signaling. Mr. Sunny Kumar has explored novel therapeutic targets like E3 ligases (CHIP), PD-1/PD-L1 pathways, and HAUSP-MDM2 axes, offering valuable insights for cancer immunotherapy and personalized treatment strategies. In addition to mechanistic studies, Mr. Sunny Kumar integrates nanobiotechnology and drug delivery innovation, developing nanoparticle-based formulations capable of crossing the blood–brain barrier for targeted glioma therapy. His research on dual-drug nanotherapeutics and carbon nanotube-based diagnostic platforms has contributed to the advancement of precision medicine approaches for difficult-to-treat cancers. He has published extensively as first or corresponding author in high-impact journals such as Genes & Diseases (IF 9.4), BBA-Molecular Cell Research (IF 3.7), International Journal of Pharmaceutics (IF 5.2), and Journal of Medicinal Chemistry (IF 6.8). His scholarly output also includes multiple book chapters with Springer and Taylor & Francis, covering cancer proteomics, personalized therapy, and nanotherapeutics. Mr. Sunny Kumar serves as a peer reviewer for reputed journals, including BBA–Reviews on Cancer and Experimental Cell Research, further demonstrating his engagement in the scientific community. His research exhibits a robust methodological framework, integrating cell and molecular biology, bioinformatics, animal models, and nanocarrier engineering. Collectively, Mr. Sunny Kumar’s scientific endeavors underscore a commitment to next-generation cancer therapeutics, aiming to translate molecular discoveries into clinically viable nanomedicine solutions for precision oncology.

Profile: Scopus | ORCID | Google Scholar | RsearchGate

Featured Publications

1. Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2023). Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes & Diseases, 10(4), 1318–1350.

2. Kumar, S., Basu, M., & Ghosh, M. K. (2022). Chaperone-assisted E3 ligase CHIP: A double agent in cancer. Genes & Diseases, 9(6), 1521–1555.

3. Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2023). COVID‐19: Clinical status of vaccine development to date. British Journal of Clinical Pharmacology, 89(1), 114–149.

4. Kumar, S., Basu, M., Ghosh, P., Pal, U., & Ghosh, M. K. (2023). COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. Genes & Diseases, 10(4), 1402–1428.

5. Ghosh, M. K., Kumar, S., Ganguly, K. K., Ghosh, P., Tabassum, S., Basu, B., & Basu, M. (2023). COVID-19 and cancer: Insights into their association and influence on genetic and epigenetic landscape. Epigenomics, 15(4), 227–248.

 

Hanghang Liu | Nanomedicine | Women Researcher Award

Prof. Dr. Hanghang Liu | Nanomedicine | Women Researcher Award

Assistant Professor at China Three Gorges University | China

Prof. Dr. Hanghang Liu is an accomplished Associate Professor at China Three Gorges University, with expertise in nanomedicine, molecular imaging, and targeted drug delivery. Her academic foundation blends chemistry and preclinical medicine, enabling her to develop multifunctional nanomaterials for the diagnosis and treatment of complex diseases such as Parkinson’s disease and breast cancer. She has made significant research contributions published in high-impact journals. In addition to her research achievements, she actively mentors graduate students in the development of natural product-based nanomedicine, promoting interdisciplinary innovation in biomedical science. Prof. Liu’s work stands at the intersection of fundamental research and clinical translation, making her a leading figure in the advancement of therapeutic nanotechnologies.

Professional Profile

Scopus Profile

Education

Prof. Dr. Hanghang Liu has a strong and interdisciplinary academic foundation in chemistry and biomedical sciences. She began her academic journey at the School of Chemistry and Chemical Engineering, Henan Normal University, where she developed a solid grounding in chemical principles and research methodologies. She then advanced her studies at the Laboratory of Molecular Imaging and Nuclear Medicine at Soochow University, where she completed a doctoral degree in Chemistry with a focus on multifunctional metal nanoprobes for the diagnosis and treatment of breast cancer. Continuing in the same laboratory, she further specialized in preclinical medicine, exploring the application of multifunctional nanomaterials for the treatment of Parkinson’s disease. Her academic path reflects a seamless integration of chemistry, nanotechnology, and translational medicine, which serves as the backbone of her pioneering research in nanomedicine.

Experience

Prof. Dr. Hanghang Liu has cultivated a distinguished career in nanomedicine and molecular imaging through a combination of research, teaching, and mentorship. She currently serves as an Associate Professor at China Three Gorges University, where she leads research efforts in the development and application of natural product-based nanomedicine. In this role, she supervises six master’s students and contributes to the advancement of interdisciplinary research in the Natural Products Research and Utilization Laboratory. Prior to this, she gained valuable experience as a Research Assistant at Soochow University’s Laboratory of Molecular Imaging and Nuclear Medicine, where she was deeply involved in cutting-edge projects related to nanoparticle-based diagnostics and therapeutics for neurodegenerative diseases and cancer. Throughout her professional journey, Prof. Liu has demonstrated a strong commitment to innovation and academic excellence, consistently contributing to high-impact research and nurturing future scientific talent.

Research Interests

Prof. Dr. Hanghang Liu’s research interests lie at the intersection of nanotechnology, molecular imaging, and biomedical applications. She focuses on the design and development of multifunctional nanomaterials for the diagnosis and treatment of neurodegenerative diseases, particularly Parkinson’s disease, and various cancers such as breast cancer. Her work emphasizes the use of metal-based nanoprobes, biomimetic nanoparticles, and natural product-derived nanomedicine to enhance therapeutic efficacy and targeting precision. Additionally, she is interested in the mechanisms of autophagy, oxidative stress modulation, and immune activation through nanoplatforms. Her research aims to bridge fundamental science with clinical application, advancing the field of translational nanomedicine.

Publications

Inhibiting Immune Crosstalk by Modulation of the Intracellular Function and Extracellular Environment of Diseased Microglia to Boost Parkinson’s Disease Therapy

Recent Advance in Sensitive Detection of Demethylase FTO

The Label- and Laser-Free Autocatalytic Nucleic Acid Amplification Reaction for the Sensitive miRNA Detection

Hijacking Endogenous Iron to Amplify Lysosomal-Mitochondrial Cascade Damage for Boosting Anti-Tumor Immunotherapy

Conclusion

Prof. Dr. Hanghang Liu is a highly suitable and deserving candidate for the Research for Women Researcher Award. Her pioneering work in developing multifunctional nanoprobes for the diagnosis and therapy of complex diseases like Parkinson’s and breast cancer showcases her as a forward-thinking and impactful researcher. With continued efforts toward global engagement and outreach, she is well-poised to shape the future of nanomedicine and inspire women in science worldwide.